CRISPR and Cas Gene Market Size, Trends & Forecast, 2032 

CRISPR and Cas Gene Market Size - By Product & Services (Product {Kits & Enzymes, Antibodies, Libraries}, Services {Cell Line Engineering}), Application (Genome Engineering, Epigenetics), End-use, Global Forecast, 2023 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp;Market definition

1.2&nbsp;&nbsp;&nbsp;Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp;Forecast parameters

1.4&nbsp;&nbsp;&nbsp;COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp;Data validation

1.6&nbsp;&nbsp;&nbsp;Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp; Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp;CRISPR and Cas gene industry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Product &amp; services trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

2.1.5&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;CRISPR and Cas Gene Industry Insights 

3.1&nbsp;&nbsp;&nbsp;Industry segmentation

3.2&nbsp;&nbsp;&nbsp;Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp;Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing need for novel therapeutics

3.2.1.2&nbsp;&nbsp;&nbsp;Rising demand for gene editing

3.2.1.3&nbsp;&nbsp;&nbsp;Rising incidence of cancer

3.2.2&nbsp;&nbsp;&nbsp;Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Off target effects of crsipr technology

3.2.2.2&nbsp;&nbsp;&nbsp;High cost factor, intellectual property disputes

3.3&nbsp;&nbsp;&nbsp;Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp;By product &amp; services

3.3.2&nbsp;&nbsp;&nbsp;By application

3.3.3&nbsp;&nbsp;&nbsp;By end-use

3.4&nbsp;&nbsp;&nbsp;COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp;Regulatory landscape

3.6&nbsp;&nbsp;&nbsp;Pipeline analysis

3.7&nbsp;&nbsp;&nbsp;Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp;PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp;Introduction

4.2&nbsp;&nbsp;&nbsp;Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp;Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp;Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp;Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;CRISPR and Cas Gene Market Size and Forecast, By Product &amp; Services (USD Million)

5.1&nbsp;&nbsp;&nbsp;Key trends, by products &amp; services

5.2&nbsp;&nbsp;&nbsp;Product

5.2.1&nbsp;&nbsp;&nbsp;Kits &amp; Enzymes

5.2.1.1&nbsp;&nbsp;&nbsp;Vector-based Cas

5.2.1.2&nbsp;&nbsp;&nbsp;DNA-free Cas

5.2.2&nbsp;&nbsp;&nbsp;Libraries

5.2.3&nbsp;&nbsp;&nbsp;Design Tool

5.2.4&nbsp;&nbsp;&nbsp;Antibodies

5.2.5&nbsp;&nbsp;&nbsp;Other Products

5.3&nbsp;&nbsp;&nbsp;Services

5.3.1&nbsp;&nbsp;&nbsp;Cell Line Engineering

5.3.2&nbsp;&nbsp;&nbsp;gRNA Design

5.3.3&nbsp;&nbsp;&nbsp;Microbial Gene Editing

5.3.4&nbsp;&nbsp;&nbsp;DNA Synthesis

5.3.5&nbsp;&nbsp;&nbsp;Screening

Chapter 6&nbsp;&nbsp;&nbsp;CRISPR and Cas Gene Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp;Key trends, by application

6.2&nbsp;&nbsp;&nbsp;Genome Engineering

6.3&nbsp;&nbsp;&nbsp;Disease Model Studies

6.4&nbsp;&nbsp;&nbsp;Functional Genomics

6.5&nbsp;&nbsp;&nbsp;Epigenetics

6.6&nbsp;&nbsp;&nbsp;Other Applications

Chapter 7&nbsp;&nbsp;&nbsp;CRISPR and Cas Gene Market Size and Forecast, By End-use (USD Million)

7.1&nbsp;&nbsp;&nbsp;Key trends, by end-use

7.2&nbsp;&nbsp;&nbsp;Biotechnology &amp; Pharmaceutical Companies

7.3&nbsp;&nbsp;&nbsp;Academics &amp; Government Research Institutes

7.4&nbsp;&nbsp;&nbsp;Contract Research Organizations (CROs)

Chapter 8&nbsp;&nbsp;&nbsp;CRISPR and Cas Gene Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp;Key trends, by region

8.2&nbsp;&nbsp;&nbsp;North America

8.2.1&nbsp;&nbsp;&nbsp;U.S.

8.2.2&nbsp;&nbsp;&nbsp;Canada

8.3&nbsp;&nbsp;&nbsp;Europe

8.3.1&nbsp;&nbsp;&nbsp;Germany

8.3.2&nbsp;&nbsp;&nbsp;UK

8.3.3&nbsp;&nbsp;&nbsp;France

8.3.4&nbsp;&nbsp;&nbsp;Spain

8.3.5&nbsp;&nbsp;&nbsp;Italy

8.3.6&nbsp;&nbsp;&nbsp;Rest of Europe

8.4&nbsp;&nbsp;&nbsp;Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp;Japan

8.4.2&nbsp;&nbsp;&nbsp;China

8.4.3&nbsp;&nbsp;&nbsp;India

8.4.4&nbsp;&nbsp;&nbsp;Australia

8.4.5&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp;Latin America

8.5.1&nbsp;&nbsp;&nbsp;Brazil

8.5.2&nbsp;&nbsp;&nbsp;Mexico

8.5.3&nbsp;&nbsp;&nbsp;Rest of Latin America

8.6&nbsp;&nbsp;&nbsp;Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp;South Africa

8.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp;Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp;AstraZeneca plc

9.2&nbsp;&nbsp;&nbsp;Addgene

9.3&nbsp;&nbsp;&nbsp;Cellectis

9.4&nbsp;&nbsp;&nbsp;CRISPR Therapeutics

9.5&nbsp;&nbsp;&nbsp;Editas Medicine, Inc.

9.6&nbsp;&nbsp;&nbsp;Thermo Fisher Scientific, Inc.

.9.7. &nbsp;&nbsp;&nbsp;F. Hoffmann-La Roche Ltd.

9.8&nbsp;&nbsp;&nbsp;Horizon Discovery Group plc

9.9&nbsp;&nbsp;&nbsp;Editas Medicine, Inc.

9.10&nbsp;&nbsp;&nbsp;Intellia Therapeutics, Inc.

&nbsp;&nbsp;&nbsp;

CRISPR and Cas Gene Market

Get a free sample of this report